What is Cellmid?
Founded in 2004 and headquartered in Sydney, Australia, Cellmid operates within the life sciences sector. The company is dedicated to the research, development, and commercialization of innovative diagnostic and therapeutic products. Its focus areas include oncology and various chronic inflammatory diseases, with a market presence spanning Australia, the United States, and Japan. Cellmid's strategic direction is geared towards advancing healthcare solutions through scientific innovation.
How much funding has Cellmid raised?
Cellmid has raised a total of $7M across 2 funding rounds:
Debt
$1M
Share Placement
$6M
Debt (2015): $1M with participation from Platinum Road
Share Placement (2020): $6M, investors not publicly disclosed
Key Investors in Cellmid
Platinum Road
Platinum Road, operating from platinumroad.com.au, is likely a financial services or investment firm that provided debt financing to Cellmid.
What's next for Cellmid?
The recent major strategic investment positions Cellmid for accelerated growth and expanded market penetration. This capital infusion is expected to fuel further research and development initiatives, potentially leading to the launch of new products and the enhancement of existing ones. The company's focus on critical health areas like cancer and chronic inflammation suggests a strategic roadmap aimed at capturing significant market share and making a tangible impact on patient outcomes. Future developments will likely involve scaling operations and solidifying its presence in key international markets.
See full Cellmid company page
